HEALTHCARE & MEDICARE
-
Hear on HTH: Healthcare executives share new products, strategies and prospects
At last month's HLTH 2025 conference in Las Vegas, MedCity News editor-in-chief Arundhati Parmar and reporter Marissa Plescia conducted video…
Read More » -
Debunked Episode 21: Drug Price Controversy, AI in Healthcare Companies Faces Consolidation, But How Much?
The exploration of artificial intelligence companies in healthcare, the drug price debate and the latest twist in the Trump administration's…
Read More » -
As healthcare and biopharmaceutical companies embrace artificial intelligence, insurance underwriters see risks and opportunities
The development of precision medicine has transformed the life sciences industry. The identification of disease-associated biomarkers and genes may not…
Read More » -
Why “time to value” is the No. 1 metric healthcare AI customers care about
Digital health funding has remained steady this year, with artificial intelligence startups increasingly receiving a larger share of venture capital…
Read More » -
UHC taps Aeroflow Health to provide virtual nutrition services
UnitedHealthcare has formed a national partnership with Aeroflow Health to provide virtual nutrition services to members, the companies announced last…
Read More » -
UCB drug becomes first FDA-approved drug to treat extremely rare and fatal mitochondrial disease
The energy that powers the body's cells comes from tiny cellular components called mitochondria. Just as a drained battery makes…
Read More » -
The future of professional nursing: APP, MD, and machine-guided supervision
Across the United States, health systems are turning to advanced practice providers (APPs) to address an escalating crisis in access…
Read More » -
Artificial Intelligence Makes FDA’s Current Drug Approval Process Obsolete – Healthcare Blog
Steven Zecora Artificial Intelligence (“AI”) has taken root in the field of drug discovery and development and is showing signs…
Read More » -
Is Mark Cuban wrong about employers, PBMs and drug prices?
Mark Cuban has been railing against self-insured employers for some time, saying they have more power than any politician to…
Read More » -
Sarepta sees path to full FDA approval for muscle disease drug despite Phase 3 trial failure
Two of Sarepta Therapeutics' drugs to treat different genetic subtypes of Duchenne muscular dystrophy in patients failed to pass the…
Read More »